Athira Pharma (NASDAQ:ATHA – Get Rating) announced its quarterly earnings results on Thursday. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.01), MarketWatch Earnings reports.
Shares of ATHA stock opened at $8.28 on Friday. Athira Pharma has a twelve month low of $7.56 and a twelve month high of $23.64. The company’s 50-day moving average price is $11.01 and its 200-day moving average price is $11.72.
In other news, Director Kelly A. Romano bought 8,000 shares of the firm’s stock in a transaction on Thursday, March 31st. The shares were bought at an average cost of $13.11 per share, for a total transaction of $104,880.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. 14.90% of the stock is currently owned by company insiders.
A number of analysts have recently commented on ATHA shares. BTIG Research began coverage on Athira Pharma in a research report on Tuesday. They issued a “buy” rating and a $33.00 price objective for the company. Berenberg Bank initiated coverage on shares of Athira Pharma in a report on Thursday, April 21st. They set a “buy” rating and a $33.00 price objective on the stock. JMP Securities reissued a “buy” rating and set a $51.00 target price on shares of Athira Pharma in a research note on Friday, March 25th. Finally, Zacks Investment Research lowered shares of Athira Pharma from a “buy” rating to a “hold” rating in a research note on Friday, April 22nd. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $29.40.
Athira Pharma Company Profile (Get Rating)
Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease.
- Get a free copy of the StockNews.com research report on Athira Pharma (ATHA)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.